
Cabozantinib hydrochloride
CAS No. ——
Cabozantinib hydrochloride ( XL184 | BMS-907351 )
Catalog No. M19952 CAS No. ——
Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2 c-Met Kit Axl and Flt4 (IC50s: 0.035 1.3 4.6 7 and 6 nM).
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 49 | Get Quote |
![]() ![]() |
5MG | 70 | Get Quote |
![]() ![]() |
10MG | 108 | Get Quote |
![]() ![]() |
25MG | 188 | Get Quote |
![]() ![]() |
50MG | 283 | Get Quote |
![]() ![]() |
100MG | Get Quote | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameCabozantinib hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionCabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2 c-Met Kit Axl and Flt4 (IC50s: 0.035 1.3 4.6 7 and 6 nM).
-
DescriptionCabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2 c-Met Kit Axl and Flt4 (IC50s: 0.035 1.3 4.6 7 and 6 nM).
-
In Vitro——
-
In Vivo——
-
SynonymsXL184 | BMS-907351
-
PathwayAngiogenesis
-
Targetc-Met/HGFR
-
Recptorc-Kit| c-Met| VEGFR2/KDR| FLT4| Axl|RORγ|RORα
-
Research AreaCancer
-
IndicationAdrenocortical carcinoma; Bone metastases; Brain metastases; Breast Cancer; Cholangiocarcinoma; Endometrial Cancer; Ewing's sarcoma
Chemical Information
-
CAS Number——
-
Formula Weight537.96
-
Molecular FormulaC28H25ClFN3O5
-
Purity>98% (HPLC)
-
SolubilityDMSO: 80 mg/mL
-
SMILESCl.COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Yakes FM et al. Cabozantinib (XL184) a novel MET and VEGFR2 inhibitor simultaneously suppresses metastasis angiogenesis and tumor growth. Mol Cancer Ther 2011 10(12) 2298-2308.
molnova catalog



related products
-
MGCD-265
MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively.
-
TRX818
TRX-818 is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities.
-
Dihexa
Dihexa is an activator of the hepatocyte growth factor/c-Met (HGF/c-Met) systemit binds to HGF (Kd = 65 pM)and an analog of the peptide angiotensin IV.